Investor
Relations

January 13, 2025

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue

December 30, 2024

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

November 26, 2024

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy